Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03432741
Title Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mayo Clinic
Indications

cutaneous T cell lymphoma

non-Hodgkin lymphoma

breast adenocarcinoma

Hodgkin's lymphoma

Therapies

Carfilzomib

Daratumumab

Obinutuzumab

Gemcitabine

Trastuzumab

Romidepsin

Nivolumab

Rituximab

Belinostat

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.